CD95L/FasL and TRAIL in tumour surveillance and cancer therapy

Cancer Treat Res. 2006;130:141-65. doi: 10.1007/0-387-26283-0_7.

Abstract

The membrane-bound death ligands CD95L/FasL and TRAIL, which activate the corresponding death receptors CD95/Fas, TRAILR1 and TRAILR2, induce apoptosis in many tumour cells, but can also elicit an inflammatory response. This chapter focuses on the relevance of CD95L/FasL and TRAIL for the tumour surveillance function of natural killer cells and cytotoxic T-cells and discuss current concepts of utilizing these ligands in tumour therapy.

Publication types

  • Review

MeSH terms

  • Antibodies
  • Apoptosis Regulatory Proteins / genetics
  • Apoptosis Regulatory Proteins / physiology*
  • Apoptosis*
  • Fas Ligand Protein
  • Genetic Therapy
  • Humans
  • Immunologic Surveillance / immunology*
  • Inflammation*
  • Killer Cells, Natural / immunology
  • Membrane Glycoproteins / genetics
  • Membrane Glycoproteins / physiology*
  • Neoplasms / genetics
  • Neoplasms / immunology*
  • Neoplasms / therapy
  • T-Lymphocytes, Cytotoxic / immunology
  • TNF-Related Apoptosis-Inducing Ligand
  • Tumor Necrosis Factor-alpha / genetics
  • Tumor Necrosis Factor-alpha / physiology*
  • Tumor Necrosis Factors / genetics
  • Tumor Necrosis Factors / physiology*

Substances

  • Antibodies
  • Apoptosis Regulatory Proteins
  • FASLG protein, human
  • Fas Ligand Protein
  • Membrane Glycoproteins
  • TNF-Related Apoptosis-Inducing Ligand
  • TNFSF10 protein, human
  • Tumor Necrosis Factor-alpha
  • Tumor Necrosis Factors